Abstract:The purpose of this study was to investigate the clinical value of plasma thrombomodulin (PTM) in different diseases or in different severity or complications of diseases, PTM in 979 patients and 60 healthy controls was determined by ELISA method. The results showed that the PTM level in the control group was 20.40 ± 7.72 μg/L, there was no difference in sex and ages. In chronic primary glomerular disease, the PTM level in chronic renal failure (CRF)group was higher than that in non-CRF group (P ＜ 0.01 ). PTM level ＞ 70 μg/L was defined as its positive criterion.The sensitivity, specificity and positive predictive value in PTM were 85.7%, 82.4% and 77.8% respectively. The PTM level in septemia group was higher than that in non-septemia group ( P ＜ 0.01 ), the sensitivity, specificity and positive predictive value were 86.6%, 89.5% and 76.5% respectively ( ＞ 50 μg/L as its positive criterion). With respect of multiple trauma, the PTM level in multiple organ failare (MOF) group was higher than that in non-MOF group ( P ＜0.01 ), while the sensitivity, specificity and positive predictive value were 77.8%, 77.3% and 73.7% respectively ( ＞40 μg/L as its positive criterion). For systemic lupus erythematosus (SLE), the PTM level in the patients with albuminuria was higher than that in the patients without albuminuria (P ＜ 0.01 ), and the sensitivity, specificity and positive predictive value were 77.8%, 92.3% and 93.3% respectively ( ＞ 35.54 μg/L as its positive criterion). For diabetes, the PTM level in complication group was higher than that in group without complications, the sensitivity, specificity and positive predictive value were 53.4% ,97.1% and 98.6% respectively ( ＞ 35.54 μg/L as its positive criterion).The PTM level in microangiopathy group was higher than that in macroangiopathy group (P ＜ 0.01 ). The sensitivity,specificity and positive predictive value were 71.2%, 97.1% and 97.9% respectively. Acute leukemia (AL) and multiple myeloma (MM) had higher PTM level and PTM level was extremely high when renal failure developed ( P ＜ 0.01 ). As compared the acute stage with the restoration stage in stroke, pre-chemotherapeutics with post-chemotherapeutics in AL and MM, and pre-operation with post-operation in cancer, the PTM level was connected with clinical development. The PTM level in the patients with microangiopathy was higher than that in the patients with macroangiopathy (P＜ 0.01 ). The defined PTM level was higher than its normal upper limit as PTM positive criterion in microangiopathy diseases, the sensitivity, specificity and positive predictive value were 77.7%, 71.2% and 75.6% respectively. It is concluded that PTM level is a good criterion in evaluating the microangiopathy, and PTM is also a valuable indicator in prediction or assessment of the severity of diseases, or evaluation of therapeutic effectiveness.

[Detection and Clinical Significance of Plasma Urokinase-Type Plasminogen Activator and Its Soluble Receptor in Patients with Multiple Myeloma].

[Expression of Microrna-221/222 in Patients with Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma].

Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels

Urine PLA2R Antibody Detection in Hazard Stratification of PLA2R-Associated Membranous Nephropathy.

Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases

Plasma-soluble Urokinase-Type Plasminogen Activator Receptor Levels Are Associated with Clinical and Pathological Activities in Lupus Nephritis: a Large Cohort Study from China

Measurement and Clinical Significance of Serum DKK-1 and Srankl Levels in Multiple Myeloma

Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Level as a Predictor of the Severity of Community-Acquired Pneumonia

Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease

Detection of plasma soluble Fas in patients with multiple myeloma

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma

[Quantitative Detection and Integrality Analysis of Plasma Circulating Cell-Free DNA in Multiple Myeloma]

The ratio of serum urea nitrogen to albumin is a better predictor of OS in MM patients than urea nitrogen alone

Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Systemic Lupus Erythematosus Patients

Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method

Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals

Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis

[Expression and Clinical Significance of LINC00475 in Multiple Myeloma]

Expressions of interleukin 6,tumor necrosis factor α and Dickkopf1 in multiple myeloma and their clinical significance

Proteomic analysis for finding serum pathogenic factors and potential biomarkers in multiple myeloma.

Clinical Study of Plasma Thrombomodulin Detection